The function and regulation of PD-L1 in immunotherapy
PD-L1, also known as B7-H1, is a type I transmembrane protein, which is expressed in different kinds of tumor cells. It is correlated with poor clinical outcome of patients with various types of tumors. PD-L1 can regulate tumor microenvironment or tumor related immune response through suppressing T...
Saved in:
Main Authors: | Libin Guo (Author), Yao Lin (Author), Hang Fai Kwok (Author) |
---|---|
Format: | Book |
Published: |
International Association of Physical Chemists (IAPC),
2017-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Regulation of IFN-γ-mediated PD-L1 expression by MYC in colorectal cancer with wild-type KRAS and TP53 and its clinical implications
by: Libin Guo, et al.
Published: (2022) -
Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents
by: Chengliang Sun, et al.
Published: (2022) -
PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021) -
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
by: Yongshuai Jiang, et al.
Published: (2019) -
Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
by: Xi Chen, et al.
Published: (2020)